Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report)'s share price shot up 5.6% during trading on Wednesday . The company traded as high as $2.10 and last traded at $2.07. 41,245 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 81,866 shares. The stock had previously closed at $1.96.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Entera Bio in a research note on Tuesday, March 18th.
Get Our Latest Analysis on ENTX
Entera Bio Stock Down 2.2 %
The stock has a market cap of $101.29 million, a PE ratio of -8.58 and a beta of 1.47. The company has a fifty day moving average price of $1.88 and a 200 day moving average price of $2.01.
Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $0.04 million during the quarter, compared to analysts' expectations of $0.04 million. As a group, research analysts predict that Entera Bio Ltd. will post -0.28 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of ENTX. Perigon Wealth Management LLC bought a new position in Entera Bio during the 4th quarter valued at approximately $325,000. Northern Trust Corp bought a new position in Entera Bio during the 4th quarter valued at approximately $450,000. Finally, Knoll Capital Management LLC raised its position in Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after purchasing an additional 2,000,000 shares during the last quarter. Hedge funds and other institutional investors own 14.11% of the company's stock.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
See Also
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
